THERAPEUTIC MODALITIES Archives - Page 10 of 22

How to Accelerate the Synthesis of PROTACs: Strategies and Case Studies

Introduction: Targeted Protein Degradation (TPD) has emerged as a promising therapeutic modality due to its potential to develop therapeutics for...

DEL Insight: Novel Applications with the Bifunctional Linker of DNA-encoded Molecules

Due to the special configuration of the DNA encoded library (DEL), each DEL molecule carries a DNA sequence encoding its...

Emerging Drug Discovery Strategies for Targeted Protein Degradation

In the last decade, targeted protein degradation (TPD) technology has become one of the most promising methods to remove specific...

OncoWuXi Express: Review of SITC 2023 Annual Meeting

Review of SITC 2023 Annual Meeting The 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) was held...

Preclinical platform for nucleic acid drug evaluation: siRNA and mRNA therapeutics

SITC Poster #59: Since the emergence of the COVID-19 pandemic, numerous nucleic-acid therapeutics have been approved for clinical use. Distinguished...

Novel Approaches to Targeted Protein Degradation

In the last decade, targeted protein degradation (TPD) technology has become one of the most promising methods to remove specific...

Pioneering Advanced Modalities in Early Drug Discovery

New modalities such as peptides, oligonucleotides, and cell and gene therapies have revolutionized healthcare industry innovation. To meet these evolving...

Advances and Biological Evaluation of Oligonucleotide Drugs

Introduction: As a therapeutic modality, oligonucleotides have a target abundance, persistent efficacy, high specificity, greater success rate and shorter R/D...

AAV Gene Therapy: Discovery and Optimization

Viral vectors, such as AAV, have emerged as one of the most commonly used gene delivery vehicles. In this webinar,...

Knowledge Library